leisure time -WSS

leisure time

author：explore 2025-09-06 02:03:53 - browse：82

Susan Tousi is leaving Illumina to become CEO of cancer liquid-biopsy startup Delfi. Nasdaq

Delfi Diagnostics, a startup devising new ways to use routine blood draws to detect early signs of cancer, told STAT Thursday that it has appointed Susan Tousi, chief commercial officer for genomics giant Illumina, as its new CEO. She is the fourth senior executive to leave Illumina since June.

Tousi will start next week, just in time for the J.P. Morgan Healthcare Conference, while founding CEO Victor Velculescu will remain on the company’s board to help guide its research programs. Tousi’s selection is part of a bid by Delfi to expand its commercial efforts and build on the initial launch of its lung cancer screening test last fall, the latest example of growing interest in the vast and increasingly competitive liquid biopsy market.

Illumina’s own ambitions to enter this space recently came undone after a prolonged battle with U.S. and European regulators finally pushed the company to announce last month that it would divest Grail, which it had acquired for $8 billion two years earlier. Bas Verhoef, Illumina’s head of region for Europe, will serve as interim chief commercial officer.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Wikipedia

WSS

Doctors push to include dialysis machines in emergency stockpile

How CRISPR works, explained in two minutes

Slovenia has suffered its worst

Pennsylvania man bitten on the head by bear during attack in his garage

As AI regulations shape up, health tech startups beg for clarity

Medicare Advantage enrollment hits roughly 33.4 million

entertainment

leisure time

leisure time

How to save PrEP access — and even expand it

With heat waves through August, officials warn of health risks

The cancer drug shortage isn’t new — and neither are the solutions

Sage considers ways to reduce costs following FDA rejection

After affirmative action ruling, medical educators look to 'holistic review'

Medicare Advantage enrollment hits roughly 33.4 million

What does generative AI mean for health care? We asked experts

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

Sports medicine is finally prioritizing gender equality

A fugitive mob suspect in Greece is betrayed by his passion for hometown Naples soccer champions

explore

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

In 'major milestone,' FDA approves first cell therapy for solid tumors

Flash flood warnings continue for parts of Missouri, Illinois

With heat waves through August, officials warn of health risks

MD Anderson's Padmanee Sharma responds to research credit suit

How CRISPR works, explained in two minutes

Wikipedia

leisure time

explore

hotspot